Insider Selling: United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells 11,000 Shares of Stock

Key Points

• Paul A. Mahon, EVP of United Therapeutics, sold 11,000 shares of the company's stock at an average price of $300.00, totaling $3.3 million, reducing his ownership by 23.02%.
• The company's stock traded at $301.50 with a market cap of $13.60 billion and a P/E ratio of 11.77, indicating a stable interest from investors amid recent stock activity.
• Despite reporting $6.41 EPS, United Therapeutics fell short of analysts' expectations of $6.80, while revenue rose by 11.7% year-over-year to $798.60 million.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $300.00, for a total value of $3,300,000.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $11,034,300. This trade represents a 23.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Down 0.2%

UTHR traded down $0.72 during trading on Monday, hitting $300.79. The company's stock had a trading volume of 255,634 shares, compared to its average volume of 515,584. The firm has a market capitalization of $13.57 billion, a P/E ratio of 11.77, a PEG ratio of 4.57 and a beta of 0.57. The stock's fifty day moving average price is $296.64 and its 200-day moving average price is $310.59. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The firm's revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the prior year, the firm posted $5.85 earnings per share. Equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on UTHR shares. Bank of America cut their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. HC Wainwright set a $400.00 target price on United Therapeutics and gave the company a "buy" rating in a research note on Thursday, July 31st. JPMorgan Chase & Co. reduced their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. UBS Group lowered their target price on United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research report on Monday, June 30th. Finally, Morgan Stanley decreased their target price on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $379.69.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently modified their holdings of UTHR. Anchor Investment Management LLC boosted its holdings in shares of United Therapeutics by 12.0% in the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after buying an additional 30 shares during the last quarter. HB Wealth Management LLC boosted its holdings in United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock worth $355,000 after acquiring an additional 35 shares in the last quarter. Hohimer Wealth Management LLC raised its stake in shares of United Therapeutics by 0.3% during the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after buying an additional 37 shares during the period. Park Avenue Securities LLC lifted its stake in shares of United Therapeutics by 1.7% in the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company's stock valued at $676,000 after purchasing an additional 39 shares during the last quarter. Finally, Applied Finance Capital Management LLC raised its position in United Therapeutics by 3.7% in the 1st quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock valued at $349,000 after purchasing an additional 40 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.